Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Gains Rights To Two US Injectables

Further Signal Of Intent For US Sterile Injectables Strategy

Executive Summary

With the $1bn deal to transfer its US dermatology and orals solids operations to Aurobindo still awaiting completion, Sandoz is expanding its portfolio of sterile injectables - a key area of focus for the company - by acquiring the rights to two products from BE Pharmaceuticals.

You may also be interested in...



Sandoz Sees Room For Improvements To US Market

Overcoming residual negative perceptions around generics, reforming Medicaid and Medicare policies that unfairly penalize generics and ensuring that “skinny label” generics can continue to be marketed are among the key priorities for Sandoz in the US, Carol Lynch, president of Sandoz Inc. and head of North America, tells Generics Bulletin in an exclusive interview.

Aurobindo-Sandoz End $1bn US Deal

Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.

Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response

Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel